John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
ZUG, Switzerland, April 05, 2016 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that Thomas Meyer, Ph.D., Chairman and Chief Executive Officer, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016, at 2:20 p.m. EDT from The Westin New York Grand Central hotel in New York City. The webcast will be available through the Events and Presentations page in the Investors section of the Company's website (www.aurismedical.com).
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".
Company contact: Cindy McGee, Head of Investor Relations and Corporate Communications +41 61 201 1350, [email protected] Agency contact: Matthew P. Duffy, Managing Director, LifeSci Advisors 212-915-0685, [email protected]
